Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
34. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
35. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
36. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
37. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
38. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
39. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
40. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
42. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
43. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
44. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
45. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
46. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
47. Cow’s milk allergy: the future
- Dr. Carina Venter
-
48. Cow's milk allergy: management
- Dr. Carina Venter
-
49. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
50. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
51. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
52. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
53. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
54. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
55. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
56. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
57. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
58. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
60. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
61. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
62. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
63. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
64. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
65. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
66. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
67. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
68. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
69. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
70. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
71. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
72. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
73. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
74. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
75. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
76. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
77. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
78. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
79. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
80. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
81. AI and big data in drug discovery
- Mr. Ed Addison
-
82. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
83. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
84. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
85. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
86. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
87. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
88. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
89. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
90. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
91. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
92. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
93. New drugs for asthma
- Prof. Peter Barnes
-
94. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
95. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- Lecture outline (1)
- Antibody-drug conjugate: modality
- Antibody-drug conjugate: heterogeneity
- Antibody-drug conjugate: the opportunity
- Antibody-drug conjugate: analytes
- Antibody-drug conjugate: typical in vivo PK
- ADC PK: examples
- Lecture outline (2)
- Cellular PK of released drug (1)
- Cellular PK of released drug (2)
- Cellular PK of ADC
- Cellular PK of ADC: the parameters
- Sensitivity analysis: cellular PK model
- Lecture outline (3)
- Mechanism-based PK/PD model for ADCs
- Case study with Brentuximab Vedotin
- Step 1: intracellular payload concentrations
- Step 2: MMAE PK in plasma & tumor tissue
- Step 3: SGN-35 PK in mouse plasma
- Step 4: a multi-scale integrated tumor model
- Step 4: prediciting tumor MMAE using the model
- Step 5: model integration
- Step 5: predicting data with the PK/PD model
- Step 6: SGN-35 & MMAE PK in cancer patients
- Step 7: preclinical to clinical translation of the model
- Step 7: PK/PD model clinical trial simulations
- Step 7: clinical trial simulation results
- Step 7: simulations vs. published results
- Lecture outline (4)
- Platform PBPK model for ADCs: approach (1)
- Platform PBPK model for ADCs: approach (2)
- ADC PBPK Model: Kadcyla® case study
- Step-1: unconjugated/released drug PK
- Step 2: ADC stability (DAR vs. time)
- Step-3: predicting preclinical PK: ADC
- Step-3: predicting preclinical PK: released drug
- Step-4: prediction of human PK (scale-up) (1)
- Step-4: prediction of human PK (scale-up) (2)
- Analysis of determinants for ADC PK
- Lecture summary
- Acknowledgements
Topics Covered
- Antibody drug conjugates (ADCs) and their uses
- Different ways to measure ADCs in the cell
- Typical ADC PK in cells
- Modeling the cellular PK of ADCs
- Modeling the tumor PK of ADCs
- 7 steps
- Modeling whole-body PK of ADCs
- Combining PK and PD models
- Kadcyla® case study
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Shah, D.K. (2019, June 30). Modeling of antibody-drug conjugate pharmacokinetics [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 31, 2024, from https://doi.org/10.69645/LXCF1517.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Dhaval K. Shah has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Immunology & Inflammation
Transcript
Please wait while the transcript is being prepared...
0:00
The topic of this presentation is "Modeling of Antibody-Drug Conjugate Pharmacokinetics".
My name is Dhaval K.Shah,
I'm an Associate Professor in
the Department of Pharmaceutical Sciences at the State University of New York at Buffalo.
0:14
Here's the outline for today's talk.
I'll mainly go over the basic tenets of antibody-drug conjugate pharmacokinetics.
How the profiles typically look like, and then we will
go over several examples of mathematical modeling,
the pharmacokinetics of ADCs at the cellular level,
at the tumor level, and at the whole-body level.
0:35
So, as the name suggests,
antibody-drug conjugates are basically conjugates of
antibodies with potent small molecule drugs.
As shown on the left, over here,
an antibody is basically a molecule with 150 Kilodaltons in size;
the ability of an antibody to specifically bind to a target is really
what makes them attractive for targeting certain tissues within the body.
However, small molecules which can be very potent some times don't have the selectivity.
So, what is done, basically these drugs are attached to antibodies and
this conjugate is now able to bring
the drugs to the desired location with the help of the antibody.
What is shown here is a cartoon of antibody-drug conjugates.
It consists of three different components: your own antibody,
you have a chemical linker, and you have a drug.
On average, the amount of drug on an antibody can range from
2 to 12 and this ratio is known as the Drug-Antibody Ratio or DAR.
What is shown in the middle is a typical mechanism of action of ADCs.
When the ADCs are administered in the systemic circulation,
it circulates in the system and goes outside the cell which expresses
the target that the antibody portion of the ADC binds.
Then the target internalizes the ADC and within the cell,
depending on the nature of the linker,
the small molecule drug is released and then
the small molecule drug can supposedly diffuse
it in the cytosol and go to
the desired location, such as if the small molecule is a tubulin binder,
then it will go to tubulins and bind there.
Or, if it is a DNA damaging agent, it will go to the nucleus and that will lead to
the pharmacology and most of the time this pharmacology is the killing of a cell.
While the antibody-drug conjugate platform can be used to treat any disease per se,
cancer as a disease has the most potential and there are four FDA approved ADCs out there-
all approved for cancer.
So, for today's talk, we'll be mainly focusing on
oncology usage of the antibodies-drug conjugate.